Relationship Between Plasma Aldosterone Concentrations and Non-Alcoholic Fatty Liver Disease Diagnosis in Patients with Hypertension: A Retrospective Cohort Study

References

• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. doi:10.1016/S2468-1253(19)30039-1
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou F, Wang W, et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71(5):1851–1864. doi:10.1002/hep.31150
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559–1569. doi:10.1056/NEJMoa2029349
   PubMed Web of Science ®Google Scholar
• Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238. doi:10.1038/s41575-020-00381-6
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904. doi:10.1016/j.jhep.2018.05.036
   PubMed Web of Science ®Google Scholar
• Cai X, Wang M, Liu S, et al. Establishment and validation of a nomogram that predicts the risk of type 2 diabetes in obese patients with non-alcoholic fatty liver disease: a longitudinal observational study. Am J Transl Res. 2022;14(7):4505–4514.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Cuevas J, Lucano-Landeros S, López-Cifuentes D, Santos A, Armendariz-Borunda J. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: current Therapeutic Strategies. Cancers. 2022;15(1):23. doi:10.3390/cancers15010023
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357. doi:10.1097/01.hjh.0000431740.32696.cc
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–1705. doi:10.1136/gutjnl-2020-320622
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021;22(21):11629. doi:10.3390/ijms222111629
   PubMed Web of Science ®Google Scholar
• Ma J, Hwang S-J, Pedley A, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66(2):390–397. doi:10.1016/j.jhep.2016.09.022
   PubMed Web of Science ®Google Scholar
• Johnston MP, Patel J, Byrne CD. Causes of mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD). Curr Pharm Des. 2020;26(10):1079–1092. doi:10.2174/1381612826666200128094231
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352. doi:10.1016/j.jhep.2017.09.021
   PubMed Web of Science ®Google Scholar
• Gao X, Yamazaki Y, Tezuka Y, et al. Pathology of aldosterone biosynthesis and its action. Tohoku J Exp Med. 2021;254(1):1–15. doi:10.1620/tjem.254.1
   PubMed Web of Science ®Google Scholar
• Yuan Y, Li N, Liu Y, et al. Positive association between plasma aldosterone concentration and white matter lesions in patients with hypertension. Front Endocrinol. 2021;12:753074. doi:10.3389/fendo.2021.753074
   PubMed Web of Science ®Google Scholar
• Zhu Q, Heizhati M, Lin M, et al. Higher plasma aldosterone concentrations are associated with elevated risk of aortic dissection and aneurysm: a case-control study. Hypertension. 2022;79(4):736–746. doi:10.1161/HYPERTENSIONAHA.121.18342
   PubMed Web of Science ®Google Scholar
• Lin M, Heizhati M, Gan L, et al. Higher aldosterone is associated with increased renal impairment risk in patients with hypertension and abnormal glucose metabolism: a longitudinal study. J Hypertens. 2022;40(3):561–569. doi:10.1097/HJH.0000000000003049
   PubMed Web of Science ®Google Scholar
• Kim KJ, Hong N, Yu MH, et al. Time-dependent risk of atrial fibrillation in patients with primary aldosteronism after medical or surgical treatment initiation. Hypertension. 2021;77(6):1964–1973. doi:10.1161/HYPERTENSIONAHA.120.16909
   PubMed Web of Science ®Google Scholar
• Mathew JT, Patni H, Chaudhary AN, et al. Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. Am J Physiol Renal Physiol. 2008;295(1):F73–F81. doi:10.1152/ajprenal.00435.2007
   PubMed Web of Science ®Google Scholar
• Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes. 2010;17(3):199–204. doi:10.1097/med.0b013e3283391989
   PubMed Web of Science ®Google Scholar
• Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res. 2013;50(2):89–99. doi:10.1159/000345243
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Y, Chen T, et al. Role of aldosterone in the activation of primary mice hepatic stellate cell and liver fibrosis via NLRP3 inflammasome. J Gastroenterol Hepatol. 2020;35(6):1069–1077. doi:10.1111/jgh.14961
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen X, Chen Q, et al. Non-alcoholic fatty liver disease and hypokalemia in primary aldosteronism among Chinese population. Front Endocrinol. 2021;12:565714. doi:10.3389/fendo.2021.565714
   PubMed Web of Science ®Google Scholar
• Fallo F, Dalla Pozza A, Tecchio M, et al. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. AM J HYPERTENS. 2009;23(1):2–5. doi:10.1038/ajh.2009.206
   PubMed Web of Science ®Google Scholar
• Kumar A, Blackshear C, Subauste JS, et al. Fatty liver disease, women, and aldosterone: finding a link in the Jackson Heart Study. J Endocr Soc. 2017;1(5):460–469. doi:10.1210/js.2017-00055
   PubMedGoogle Scholar
• Noguchi R, Yoshiji H, Ikenaka Y, et al. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int J Mol Med. 2010;26(3):407–413.
   PubMed Web of Science ®Google Scholar
• Gamliel-Lazarovich A, Raz-Pasteur A, Coleman R, et al. The effects of aldosterone on diet-induced fatty liver formation in male C57BL/6 mice: comparison of adrenalectomy and mineralocorticoid receptor blocker. Eur J Gastroenterol Hepatol. 2013;25(9):1086–1092. doi:10.1097/MEG.0b013e328360554a
   PubMed Web of Science ®Google Scholar
• Farrell GC, Chitturi S, Lau GK, Sollano JD. Asia-Pacific Working Party on N Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22:775–777. doi:10.1111/j.1440-1746.2007.05002.x
   PubMed Web of Science ®Google Scholar
• Hu J, Cai X, Li N, et al. Association between triglyceride glucose index-waist circumference and risk of first myocardial infarction in Chinese hypertensive patients with obstructive sleep apnoea: an observational cohort study. Nat Sci Sleep. 2022;14:969–980. doi:10.2147/NSS.S362101
   PubMed Web of Science ®Google Scholar
• Cai X, Li N, Hu J, et al. Nonlinear relationship between Chinese visceral adiposity index and new-onset myocardial infarction in patients with hypertension and obstructive sleep apnoea: insights from a Cohort Study. J Inflamm Res. 2022;15:687–700. doi:10.2147/JIR.S351238
   PubMed Web of Science ®Google Scholar
• Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916. doi:10.1210/jc.2015-4061
   PubMed Web of Science ®Google Scholar
• Wang X, Luo Q, Wang M, et al. Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism. Hypertens Res. 2021;44(4):426–434. doi:10.1038/s41440-020-00589-8
   PubMed Web of Science ®Google Scholar
• Gao X, Fan JG; Study Group of Liver and Metabolism, Chinese Society of Endocrinology. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes. 2013;5(4):406–415. doi:10.1111/1753-0407.12056
   PubMed Web of Science ®Google Scholar
• Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51(6):1061–1067. doi:10.1016/j.jhep.2009.09.001
   PubMed Web of Science ®Google Scholar
• Fan JG, Jia JD, Li YM, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: published in Chinese on Chinese Journal of Hepatology 2010; 18:163–166. J Dig Dis. 2011;12(1):38–44. doi:10.1111/j.1751-2980.2010.00476.x
   PubMed Web of Science ®Google Scholar
• VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-Value. Ann Intern Med. 2017;167(4):268–274. doi:10.7326/M16-2607
   PubMed Web of Science ®Google Scholar
• Wu S, Wu F, Ding Y, et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6:33386. doi:10.1038/srep33386
   PubMed Web of Science ®Google Scholar
• Niederseer D, Wernly S, Bachmayer S, et al. Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) is independently associated with cardiovascular risk in a large Austrian screening cohort. J Clin Med. 2020;9(4):1065. doi:10.3390/jcm9041065
   PubMed Web of Science ®Google Scholar
• Møller S, Kimer N, Kronborg T, et al. Nonalcoholic fatty liver disease and cardiovascular disease: overlapping mechanisms. Semin Liver Dis. 2021;41(3):235–247. doi:10.1055/s-0041-1725022
   PubMedGoogle Scholar
• Song QR, Liu SL, Bi YG, et al. Non-alcoholic fatty liver disease is associated with cardiovascular outcomes in subjects with prediabetes and diabetes: a prospective community-based cohort study. Front Cardiovasc Med. 2022;9:889597. doi:10.3389/fcvm.2022.889597
   PubMed Web of Science ®Google Scholar
• Deng YY, Zhong QW, Zhong HL, Xiong F, Ke YB, Chen YM. Higher Healthy Lifestyle Score is associated with lower presence of non-alcoholic fatty liver disease in middle-aged and older Chinese adults: a community-based cross-sectional study. Public Health Nutr. 2021;24(15):5081–5089. doi:10.1017/S1368980021000902
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Moustaki M, Paschou SA, Vakali EC, et al. Secondary diabetes mellitus due to primary aldosteronism [published online ahead of print, 2022 Aug 24]. Endocrine. 2022. doi:10.1007/s12020-022-03168-8
   PubMed Web of Science ®Google Scholar
• Li P, Zhang XN, Pan CM, et al. Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes. Horm Metab Res. 2011;43(7):464–469. doi:10.1055/s-0031-1277226
   PubMed Web of Science ®Google Scholar
• Ma H, Gomez V, Lu L, et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroen Hepatol. 2008;24(2):233–237. doi:10.1111/j.1440-1746.2008.05548.x
   PubMed Web of Science ®Google Scholar
• Fukushima J, Kamada Y, Matsumoto H, et al. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res. 2009;39(7):724–738. doi:10.1111/j.1872-034X.2009.00509.x
   PubMed Web of Science ®Google Scholar
• Dong Z, Zhuang Q, Ye X, et al. Adiponectin Inhibits NLRP3 inflammasome activation in nonalcoholic steatohepatitis via AMPK-JNK/ErK1/2-NFκB/ROS signaling pathways. Front Med. 2020;7:546445. doi:10.3389/fmed.2020.546445
   PubMed Web of Science ®Google Scholar
• Kumagai E, Adachi H, Jacobs DR, et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension. 2011;58(6):1043–1048. doi:10.1161/HYPERTENSIONAHA.111.180521
   PubMed Web of Science ®Google Scholar
• Zhang X, Wong GL, Yip TC, et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76(2):469–482. doi:10.1002/hep.32294
   PubMed Web of Science ®Google Scholar
• Cai X, Li N. Association between use of spironolactone and risk of stroke in hypertensive patients: a cohort study. Pharmaceuticals. 2022;16(1):57. doi:10.3390/ph16010057
   Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Zafeiriadou E, et al. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst. 2011;12(4):498–503. doi:10.1177/1470320311402110
   PubMed Web of Science ®Google Scholar
• Wabitsch S, McCallen JD, Kamenyeva O, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022;77(3):748–760. doi:10.1016/j.jhep.2022.03.010
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis [published correction appears in JAMA Intern Med. 2017 May 1;177(5):747]. JAMA Intern Med. 2017;177(5):633–640. doi:10.1001/jamainternmed.2016.9607
   PubMed Web of Science ®Google Scholar
• Ito D, Shimizu S, Inoue K, et al. Comparison of Ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40(10):1364–1372. doi:10.2337/dc17-0518
   PubMed Web of Science ®Google Scholar
• Kumar J, Memon RS, Shahid I, et al. Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map. Dig Liver Dis. 2021;53(1):44–51. doi:10.1016/j.dld.2020.08.021
   PubMedGoogle Scholar